Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 3(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05266924Phase 3Unknown

Recombinant Follicle-stimulating Hormone in Treatment for Infertility

Role: lead

NCT04914195Phase 3Completed

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Role: lead

NCT04834908Phase 1Terminated

Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection

Role: lead

NCT00876824Phase 3Completed

To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

Role: lead

All 4 trials loaded